HAYA Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
40
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$63.1M
- Investors
-
16
HAYA Therapeutics General Information
Description
Operator of a precision therapeutics company intended to discover and develop tissue and cell-selective genomic medicines for fibrotic diseases. The company's therapeutics utilize biopharmaceutical therapy to target a heart-specific regulator of fibrosis and other serious health conditions associated with aging, including cancer, enabling physicians to block myocardial fibrosis and treat heart-related illnesses with efficacy and safety.
Contact Information
Website
www.hayatx.comCorporate Office
- Route de la Corniche 5B
- Batiment Alanine, Epalinges
- 1066 Lausanne
- Switzerland
Corporate Office
- Route de la Corniche 5B
- Batiment Alanine, Epalinges
- 1066 Lausanne
- Switzerland
HAYA Therapeutics Timeline
HAYA Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series A) | 25-Apr-2025 | $63.1M | Completed | Clinical Trials - Phase 1 | ||
| 8. Later Stage VC | 04-Sep-2024 | Completed | Clinical Trials - Phase 1 | |||
| 7. Seed Round | 09-Feb-2022 | Completed | Clinical Trials - Phase 1 | |||
| 6. Seed Round | 01-Nov-2020 | Completed | Clinical Trials - Phase 1 | |||
| 5. Accelerator/Incubator | 01-Jan-2019 | Completed | Startup | |||
| 4. Grant | 31-Jan-2018 | Completed | Startup | |||
| 3. Accelerator/Incubator | 06-Oct-2017 | Completed | Startup | |||
| 2. Grant | 03-Oct-2017 | $10.4K | $40.4K | Completed | Startup | |
| 1. Accelerator/Incubator | 24-May-2017 | $40.4K | $40.4K | Completed | Startup |
HAYA Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed | ||||||||
| Seed | 15,999,390 | $0.011713 | $0.88 | $0.88 | 1x | $0.88 | 11.95% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
HAYA Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
HAYA Therapeutics Patents
HAYA Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026105091-A1 | Compositions and methods to modulate transposable elements governing cell-state transitions | Pending | 18-Nov-2024 | ||
| AU-2024366605-A1 | Compositions and methods of modulating long noncoding transcripts associated with ards induced pulmonary fibrosis | Pending | 25-Oct-2023 | ||
| EP-4798715-A1 | Compositions and methods of modulating long noncoding transcripts associated with ards induced pulmonary fibrosis | Pending | 25-Oct-2023 | ||
| WO-2025088373-A1 | Compositions and methods of modulating long noncoding transcripts associated with ards induced pulmonary fibrosis | Inactive | 25-Oct-2023 | ||
| AU-2024350974-A1 | Compositions and methods to modulate idiopathic pulmonary fibrotic associated long noncoding rnas | Pending | 25-Sep-2023 | C12N15/113 |
HAYA Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
HAYA Therapeutics Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Earlybird Venture Capital | Venture Capital | Minority | ||
| LifeLink Ventures | Venture Capital | Minority | ||
| ND Capital | Venture Capital | Minority | ||
| Sofinnova Partners | Venture Capital | Minority |
HAYA Therapeutics FAQs
-
When was HAYA Therapeutics founded?
HAYA Therapeutics was founded in 2017.
-
Where is HAYA Therapeutics headquartered?
HAYA Therapeutics is headquartered in Lausanne, Switzerland.
-
What is the size of HAYA Therapeutics?
HAYA Therapeutics has 40 total employees.
-
What industry is HAYA Therapeutics in?
HAYA Therapeutics’s primary industry is Drug Discovery.
-
Is HAYA Therapeutics a private or public company?
HAYA Therapeutics is a Private company.
-
What is the current valuation of HAYA Therapeutics?
The current valuation of HAYA Therapeutics is .
-
What is HAYA Therapeutics’s current revenue?
The current revenue for HAYA Therapeutics is .
-
How much funding has HAYA Therapeutics raised over time?
HAYA Therapeutics has raised $101M.
-
Who are HAYA Therapeutics’s investors?
Alexandria Venture Investments, Earlybird Venture Capital, LifeLink Ventures, ND Capital, and Sofinnova Partners are 5 of 16 investors who have invested in HAYA Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
